Vir Biotechnology, Inc. (VIR): who owns it and who trades it
As of Nov 16, 2026, VIR insiders reported 33 open-market sales worth $8.2M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was SVF Endurance (Cayman) Ltd (10% owner), with $4.1M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Vir Biotechnology
From the latest filingsOverall: more selling than buying. Famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns VIR
235 funds and institutions reported VIR shares worth $1.5B at the end of Q2 2026, about 88% of the company. The largest holder is BlackRock, Inc. with 12.3%.
Funds and institutions (13F) 88%Everyone else 12%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 20.68M | 12.26% | $211M | +15% |
| ARCH Venture Management, LLC | 12.69M | 7.53% | $129M | -2% |
| Vanguard Portfolio Management LLC | 11.50M | 6.82% | $117M | +25% |
| Sb Investment Advisers (uk) Ltd | 10.95M | 6.49% | $112M | No change |
| State Street Corp | 9.96M | 5.91% | $102M | +40% |
| GSK plc | 8.55M | 5.07% | $87.1M | No change |
| Vanguard Capital Management LLC | 6.39M | 3.79% | $65.1M | +19% |
| Point72 Asset Management, L.P. | 5.67M | 3.36% | $57.7M | +190% |
| Geode Capital Management, LLC | 3.35M | 1.99% | $34.1M | +26% |
| Dimensional Fund Advisors LP | 3.12M | 1.85% | $31.8M | +21% |
| ADAR1 Capital Management, LLC | 2.46M | 1.46% | $25M | -10% |
| Goldman Sachs Group Inc | 2.37M | 1.40% | $24.1M | -27% |
| FMR LLC (Fidelity) | 2.32M | 1.37% | $23.6M | +12% |
| Morgan Stanley | 2.21M | 1.31% | $22.5M | -23% |
| Nuveen, LLC | 1.98M | 1.18% | $20.2M | +95% |
| Pictet Asset Management Holding SA | 1.95M | 1.16% | $19.9M | +32% |
| Boxer Capital Management, LLC | 1.87M | 1.11% | $19M | No change |
| Northern Trust Corp | 1.43M | 0.85% | $14.6M | +45% |
| Hudson Bay Capital Management LP | 1.36M | 0.81% | $13.9M | -7% |
| GordonMD Global Investments LP | 1.35M | 0.80% | $13.8M | -11% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, VIR insiders reported $0 of open-market purchases and $8.2M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Verneuil Vanina de | Vice president | Sale plan | 2,407 | $11.10 | $26.7K | Form 4 |
| Nov 2, 2026 | Verneuil Vanina de | Vice president | Sale plan | 1,343 | $11.33 | $15.2K | Form 4 |
| Jun 1, 2026 | Janet Napolitano | Director | Sale plan | 3,200 | $9.45 | $30.2K | Form 4 |
| Jun 1, 2026 | Brent Sabatini | Vice president | Sale plan | 379 | $9.45 | $3.6K | Form 4 |
| May 1, 2026 | Vicki L Sato | Director | Sale plan | 22,000 | $10.05 | $221K | Form 4 |
| Apr 6, 2026 | Backer Marianne De | CEO | Sale plan | 72,559 | $9.16 | $665K | Form 4 |
| Apr 1, 2026 | Vicki L Sato | Director | Sale plan | 22,000 | $9.07 | $200K | Form 4 |
| Mar 23, 2026 | Brent Sabatini | Vice president | Sale plan | 7,711 | $9.12 | $70.3K | Form 4 |
| Mar 2, 2026 | Vicki L Sato | Director | Sale plan | 200 | $9.98 | $2K | Form 4 |
| Mar 2, 2026 | Vicki L Sato | Director | Sale plan | 21,800 | $9.50 | $207K | Form 4 |
| Feb 25, 2026 | Mark Eisner | Vice president | Sale plan | 1,889 | $9.82 | $18.5K | Form 4 |
| Feb 25, 2026 | Verneuil Vanina de | Vice president | Sale plan | 13,700 | $9.82 | $135K | Form 4 |
| Feb 24, 2026 | Vicki L Sato | Director | Sale plan | 42,177 | $9.75 | $411K | Form 4 |
| Feb 24, 2026 | Vicki L Sato | Director | Sale plan | 200 | $10.26 | $2.1K | Form 4 |
| Feb 24, 2026 | Brent Sabatini | Vice president | Sale plan | 1,430 | $9.53 | $13.6K | Form 4 |
| Feb 24, 2026 | Jason O'Byrne | CFO | Sale plan | 1,634 | $9.53 | $15.6K | Form 4 |
| Feb 24, 2026 | Mark Eisner | Vice president | Sale plan | 1,616 | $9.53 | $15.4K | Form 4 |
| Feb 24, 2026 | Verneuil Vanina de | Vice president | Sale plan | 3,117 | $9.53 | $29.7K | Form 4 |
| Feb 24, 2026 | Backer Marianne De | CEO | Sale plan | 14,762 | $9.53 | $141K | Form 4 |
| Feb 23, 2026 | Brent Sabatini | Vice president | Sale plan | 1,829 | $7.45 | $13.6K | Form 4 |
| Feb 23, 2026 | Jason O'Byrne | CFO | Sale plan | 2,089 | $7.45 | $15.6K | Form 4 |
| Feb 23, 2026 | Verneuil Vanina de | Vice president | Sale plan | 4,445 | $7.45 | $33.1K | Form 4 |
| Feb 23, 2026 | Backer Marianne De | CEO | Sale plan | 19,039 | $7.45 | $142K | Form 4 |
| Feb 13, 2026 | Brent Sabatini | Vice president | Sale plan | 1,530 | $7.79 | $11.9K | Form 4 |
| Feb 2, 2026 | Vicki L Sato | Director | Sale plan | 22,000 | $7.71 | $170K | Form 4 |
| Jan 2, 2026 | Vicki L Sato | Director | Sale plan | 22,000 | $5.93 | $130K | Form 4 |
| Dec 1, 2025 | SVF Endurance (Cayman) Ltd +2 | 10% owner | Sale plan | 191,854 | $5.98 | $1.1M | Form 4 |
| Dec 1, 2025 | Vicki L Sato | Director | Sale plan | 22,000 | $6.00 | $132K | Form 4 |
| Nov 28, 2025 | Softbank Vision Fund (Aiv M1) L.P. +2 | 10% owner | Sale plan | 61,493 | $6.44 | $396K | Form 4 |
| Nov 26, 2025 | Softbank Vision Fund (Aiv M1) L.P. +2 | 10% owner | Sale plan | 127,938 | $6.39 | $818K | Form 4 |
| Nov 25, 2025 | SVF Endurance (Cayman) Ltd +2 | 10% owner | Sale plan | 235,971 | $6.38 | $1.5M | Form 4 |
| Nov 24, 2025 | SVF Endurance (Cayman) Ltd +2 | 10% owner | Sale plan | 227,803 | $6.15 | $1.4M | Form 4 |
| Nov 17, 2025 | Jason O'Byrne | CFO | Sale plan | 6,799 | $5.56 | $37.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| SVF Endurance (Cayman) Ltd | 10% owner | – | $4.1M | Dec 1, 2025 |
| Vicki L Sato | Director | – | $1.5M | May 1, 2026 |
| Softbank Vision Fund (Aiv M1) L.P. | 10% owner | – | $1.2M | Nov 28, 2025 |
| Backer Marianne De | Chief Executive Officer, Director | – | $947K | Apr 6, 2026 |
| Verneuil Vanina de | EVP, General Counsel, Corp Sec | – | $239K | Nov 3, 2026 |
| Brent Sabatini | SVP, Chief Accounting Officer | – | $113K | Jun 1, 2026 |
| Jason O'Byrne | EVP & Chief Financial Officer | – | $68.9K | Feb 24, 2026 |
| Mark Eisner | EVP and Chief Medical Officer | – | $34K | Feb 25, 2026 |
| Janet Napolitano | Director | – | $30.2K | Jun 1, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
VIR short interest
Moderate short interest. 9.9% of VIR shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short barely changed.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 16.87M VIR shares were sold short, 9.9% of the shares outstanding, up 3.9% from the report before. At the average daily volume of 1.42M shares, buying them all back would take about 11.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 16.87M | 9.85% | +4% | 1.42M | 11.9 |
| Oct 15, 2026 | 16.24M | 9.60% | +8% | 2.35M | 6.9 |
| Sep 30, 2026 | 14.98M | 8.85% | -24% | 2.14M | 7.0 |
| Sep 15, 2026 | 19.66M | 11.62% | -8% | 2.08M | 9.5 |
| Aug 31, 2026 | 21.34M | 12.61% | +9% | 1.92M | 11.1 |
| Aug 14, 2026 | 19.60M | 11.58% | +3% | 1.44M | 13.6 |
| Jul 31, 2026 | 19.04M | 11.25% | +3% | 1.56M | 12.2 |
| Jul 15, 2026 | 18.45M | 10.94% | -4% | 1.54M | 12.0 |
| Jun 30, 2026 | 19.19M | 11.38% | +6% | 3.21M | 6.0 |
| Jun 15, 2026 | 18.08M | 10.72% | -1% | 1.52M | 11.9 |
| May 29, 2026 | 18.32M | 10.86% | +9% | 1.69M | 10.8 |
| May 15, 2026 | 16.83M | 9.98% | +4% | 1.54M | 10.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Vir Biotechnology company events
Vir Biotechnology filed 18 reports on Form 8-K in the last 12 months, 7 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026AnnouncementECLIPSE 1 TLR Certain data from the ongoing Phase 3 ECLIPSE 1 clinical trial, including the ECLIPSE 1 TLR, were presented in an oral session at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ®, in Denver, Colorado on November 8, 2026. Filing
- Nov 4, 2026ResultsReleased financial results. Filing
- Oct 28, 2026LeadershipThe Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase in the size of the Board from eight to nine members and the appointment of Suzanne Topalian, M.D., to fill the… Filing
- Oct 14, 2026AnnouncementVir Bio issued a press release announcing the entry into the Agreement and the SPA. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference. Filing
- Oct 8, 2026AnnouncementVir Biotechnology, Inc. (the Company) issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN ® dual-masked T-cell engager (TCE), for the treatment of late-line metastatic castration-resistant prostate… Filing
- Oct 1, 2026LeadershipVir Biotechnology, Inc. (the Company) announced that Aziz Sawaf, MBEE, MBA, CFA has been appointed as Executive Vice President and Chief Financial Officer and “principal financial officer” of the Company, effective as of October 5, 2026 (the Effective Date). Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jul 24, 2026LeadershipJason O’Byrne, MBA, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (Vir Bio), informed Vir Bio that he will be stepping down from his role, effective August 3, 2026, to pursue another opportunity. Filing
- Jun 10, 2026LeadershipThe Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase in the size of the Board from seven to eight members and the appointment of Timothy Coughlin, CPA, to fill the… Filing
- May 28, 2026LeadershipSaira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of… Filing
- May 6, 2026ResultsReleased financial results. Filing
- Apr 10, 2026LeadershipMark Eisner, MD, MPH, Executive Vice President and Chief Medical Officer of Vir Biotechnology, Inc. (the Company), informed the Company that he will be stepping down from his role, effective April 24, 2026. Filing
- Mar 4, 2026LeadershipThe Board of Directors of Vir Biotechnology, Inc. (Vir Bio) appointed Marianne De Backer, M.Sc., Ph.D., MBA, Vir Bio’s Chief Executive Officer and principal executive officer, to the additional position of President. Filing
- Mar 2, 2026AnnouncementAs previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on February 26, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group… Filing
- Feb 26, 2026AgreementVir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C. and Barclays Capital Inc., as representatives of the several underwriters named in Schedule I thereto (the Underwriters)… Filing
- Feb 23, 2026AgreementVir Biotechnology, Inc. (Vir Bio) and Astellas US LLC (together with its subsidiaries and affiliates (including its indirect parent, Astellas Pharma Inc.), Astellas) entered into a Collaboration and License Agreement (the Agreement). Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 16, 2025AgreementVir Biotechnology, Inc. (Vir Bio) and Norgine Pharma UK Limited (together with its affiliates in the Norgine group of companies, Norgine) entered into a License Agreement (the Agreement) with respect to certain commercial rights to the combination of tobevibart, an investigational monoclonal… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Vir Biotechnology financials
Famous investors that hold VIR
4 of the 50 well-known investors we track reported holding VIR in their latest 13F filing. The largest position is Steve Cohen's, worth $75.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 6.77M | $75.7M | 0.1% | +20% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 402,546 | $4.5M | 0.0% | -59% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 395,964 | $4.4M | 0.0% | -61% |
| Israel Englander · Millennium Management | Q3 2026 | 20,415 | $228K | 0.0% | -57% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named VIR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.6% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.6% |
| Nov 6, 2026 | ARCH Venture Fund IX, L.P. | 13D/A | 6.9% |
| Nov 6, 2026 | ARCH Venture Fund IX, L.P. | 13D/A | 6.9% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 12.4% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 12.4% |
Questions about Vir Biotechnology, Inc. (VIR) stock
Who owns the most VIR stock?
The largest reported owner of Vir Biotechnology, Inc. (VIR) is BlackRock, Inc., with 12.3% of the company. In total, 235 funds and institutions reported holding VIR at the end of Q2 2026, together about 88% of the shares. See the largest owners.
Are VIR insiders buying or selling?
In the last 12 months, VIR insiders reported no open-market purchases and 33 sales worth $8.2M. The latest trade was on Nov 3, 2026. See every trade.
What is the short interest in VIR?
As of Oct 30, 2026, 16.87M VIR shares were sold short, 9.9% of the shares outstanding, up 3.9% from the report before. At the average daily volume of 1.42M shares, buying them all back would take about 11.9 trading days (days to cover). See the history.
Which famous investors hold VIR?
4 of the 50 well-known investors we track reported VIR in their latest 13F filing, including Steve Cohen, Ken Griffin, Jim Simons. The largest position is worth $75.7M. See all holders.
Executive pay
Vir Biotechnology's chief executive was paid a total of $7.8M for the year ended Dec 31, 2025. In the last 12 months, Vir Biotechnology's executives and directors bought no stock on the open market and sold $2.9M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.